On November 1st in Marrakech, Danish pharmaceutical company Novo Nordisk officially introduced its type 2 diabetes treatment, semaglutide, to the Moroccan market. The launch took place during a major scientific conference that brought together over 400 healthcare professionals for a deep dive into the latest advancements in diabetes care.
Type 2 diabetes remains one of Morocco’s most pressing public health challenges, with an estimated 2.6 million people affected nationwide. The burden of the disease is made even heavier by its potential complications, particularly those involving the heart and kidneys, which require precise, up-to-date medical management.
Professor Nawal El Ansari, head of endocrinology at the Mohammed VI University Hospital in Marrakech, described the arrival of semaglutide as a significant step forward. She emphasized that its true value lies in being part of a serious, evidence-based treatment strategy that addresses both the symptoms and the long-term risks associated with the disease.
For Novo Nordisk, the rollout of semaglutide in Morocco reflects a broader push for innovation in chronic disease management. Dr. Ola Rifai, the company’s managing director in Morocco, praised the drug’s weekly injection format as a breakthrough in patient convenience and adherence. By simplifying the treatment regimen, she said, semaglutide offers patients greater control over their condition—and a better quality of life.
The event also featured Danish Ambassador to Morocco, Britt Bager, who underscored the importance of collaboration between Novo Nordisk and local diabetes-focused organizations. She called the partnership a concrete example of how international cooperation can enhance healthcare outcomes and access.
Throughout the summit, several leading diabetes experts—both Moroccan and international—shared the latest clinical data on semaglutide. Among them were Professors Bruno Guerci, Asmae Chadli, Hind El Iraqi, Siham El Azizi, Hassan El Ghomari, Paolo Fadini, and Atul Pathak. Their presentations highlighted the drug’s ability to improve key metabolic markers and reduce the risk of cardiovascular and renal complications—two of the most dangerous long-term effects of diabetes.
One particularly engaging session focused on the clinical diversity of patients with type 2 diabetes, emphasizing the need for personalized treatment approaches. Experts agreed that individualized care strategies are essential for maximizing outcomes in this highly variable condition.
Semaglutide works by activating GLP-1 receptors, helping to regulate blood sugar levels while also promoting weight loss. Clinical studies have shown that its benefits go beyond glycemic control, offering proven protection for the heart and kidneys—an important advancement in the holistic management of diabetes.
Founded in 1923 in Copenhagen, Novo Nordisk has grown into a global leader in the fight against diabetes and other chronic diseases. The company employs more than 77,000 people across more than 100 countries and remains at the forefront of research and innovation in metabolic health.
